The report "POP Treatment and Management / Pelvic Organ Prolapse Market by Product (Synthetic Mesh, Sutures, Pessaries, Robotic Systems), Treatment (Surgical, PFMT), Application (Cystocele, Uterine Prolapse), End User (Hospitals, ASCs), Region - Global Forecast to 2030", is valued at an estimated USD 0.77 billion in 2025. It is projected to reach USD 1.06 billion by 2030, at a CAGR of 6.6%.

Browse 345 market data Tables and 42 Figures spread through 331 Pages and in-depth TOC on "POP Treatment and Management / Pelvic Organ Prolapse Market by Product (Synthetic Mesh, Sutures, Pessaries, Robotic Systems), Treatment (Surgical, PFMT), Application (Cystocele, Uterine Prolapse), End User (Hospitals, ASCs), Region - Global Forecast to 2030"

Download PDF- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122047301

The growth of the POP Treatment and Management / Pelvic Organ Prolapse market is driven by key factors. An increasing number of aging women, coupled with risk factors such as childbirth trauma, obesity, and menopause, is contributing to a rising prevalence of pelvic floor disorders. Advancements in minimally invasive and robotic-assisted surgical techniques are enhancing treatment outcomes and patient recovery. Additionally, growing awareness, better diagnostic capabilities, and expanding access to healthcare in emerging markets are creating new opportunities for the adoption of POP treatment solutions.

By treatment, the surgical segment is expected to grow at the fastest rate in the POP Treatment and Management / Pelvic Organ Prolapse market over the forecast period.

The POP Treatment and Management / Pelvic Organ Prolapse market is divided into two main segments based on treatment: surgical and non-surgical. Surgical treatment type is further divided into colpocleisis, colporrhapy, sacrocolpopexy, sacrohysteropexy, and uterosacral or sacrospinous ligament fixation. The surgical segment of the POP Treatment and Management / Pelvic Organ Prolapse held the largest market share in 2024. The segment remains dominant as it provides effective, long-term relief for moderate to severe prolapse cases. Advancements in minimally invasive and robotic-assisted techniques have enhanced precision, reduced recovery time, and minimized complications. These innovations have increased patient and physician preference for surgical intervention. As a result, surgery is often considered the most reliable option for lasting pelvic floor support.

By end user, hospitals held the largest share of the POP Treatment and Management / Pelvic Organ Prolapse market in 2024.

Based on end users, the POP Treatment and Management / Pelvic Organ Prolapse market is divided into hospitals, specialty clinics, ambulatory surgery centers (ASCs), and others. Among these end users, the hospitals segment held the largest market share in 2024 for POP Treatment and Management / Pelvic Organ Prolapse. The hospitals segment is dominant due to the availability of advanced surgical infrastructure and skilled specialists required for complex POP procedures. Hospitals offer comprehensive pre- and post-operative care, ensuring better patient outcomes. Most robotic and minimally invasive surgeries are performed in hospital settings due to equipment needs. Additionally, higher patient trust and referral rates drive treatment volumes in hospitals.

North America dominated the global POP Treatment and Management / Pelvic Organ Prolapse market in 2024.

The POP Treatment and Management / Pelvic Organ Prolapse market is segmented into five major segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America had the largest market share in the POP Treatment and Management / Pelvic Organ Prolapse market in 2024. The region holds a dominant position due to its well-established healthcare infrastructure and high awareness of pelvic organ prolapse disorders. It has a large aging female population, contributing to a higher prevalence of POP cases. Widespread adoption of advanced technologies, including robotic-assisted surgeries, supports market growth. Strong presence of leading medical device companies drives innovation and accessibility. Additionally, favorable reimbursement policies and higher healthcare spending accelerate treatment uptake.

Key Players

Prominent players in the POP Treatment and Management / Pelvic Organ Prolapse market include Boston Scientific Corporation (US), Coloplast Group (Denmark), Intuitive Surgical Operations, Inc. (US), CooperCompanies (US), Johnson & Johnson (US), GE HealthCare (US), Integra LifeSciences Corporation (US), B. Braun SE (Germany), and pfm medical gmbh (Germany).

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.